Innovent Biologics Announces Promising Clinical Study Results for Picankibart in Psoriasis at EADV Congress 2025

Reuters

Yesterday

Innovent Biologics Announces Promising Clinical Study Results for Picankibart in Psoriasis at EADV Congress 2025

Innovent Biologics Inc., a prominent biopharmaceutical company, has announced that it will present multiple research results at the upcoming 34th European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, France, from September 17-20. The presentations will include post hoc analysis of Phase 2 and Phase 3 clinical studies of IBI112 (an IL-23p19 monoclonal antibody known as picankibart), as well as preclinical study results of IBI3013 (an IL-15 monoclonal antibody) and IAR129 (an IL-4R/OX40L bispecific antibody). These findings will be showcased via ePoster presentations. Picankibart, a cornerstone product in Innovent's pipeline, is anticipated to receive marketing approval by the end of the year, potentially offering a novel treatment option for psoriasis patients. The presentations aim to provide insight into the efficacy and safety of these innovative therapies and their potential impact on patient care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN73327) on September 16, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2567121313"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567121313\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567121313?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-16 09:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567121313","market":"fut","top_or_hot":-1,"title":"Innovent Biologics Announces Promising Clinical Study Results for Picankibart in Psoriasis at EADV Congress 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics Announces Promising Clinical Study Results for Picankibart in Psoriasis at EADV Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a>, a prominent biopharmaceutical company, has announced that it will present multiple research results at the upcoming 34th European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, France, from September 17-20. The presentations will include post hoc analysis of Phase 2 and Phase 3 clinical studies of IBI112 (an IL-23p19 monoclonal antibody known as picankibart), as well as preclinical study results of IBI3013 (an IL-15 monoclonal antibody) and IAR129 (an IL-4R/OX40L bispecific antibody). These findings will be showcased via ePoster presentations. Picankibart, a cornerstone product in Innovent's pipeline, is anticipated to receive marketing approval by the end of the year, potentially offering a novel treatment option for psoriasis patients. The presentations aim to provide insight into the efficacy and safety of these innovative therapies and their potential impact on patient care.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN73327) on September 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics Announces Promising Clinical Study Results for Picankibart in Psoriasis at EADV Congress 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics Announces Promising Clinical Study Results for Picankibart in Psoriasis at EADV Congress 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-16 09:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics Announces Promising Clinical Study Results for Picankibart in Psoriasis at EADV Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a>, a prominent biopharmaceutical company, has announced that it will present multiple research results at the upcoming 34th European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, France, from September 17-20. The presentations will include post hoc analysis of Phase 2 and Phase 3 clinical studies of IBI112 (an IL-23p19 monoclonal antibody known as picankibart), as well as preclinical study results of IBI3013 (an IL-15 monoclonal antibody) and IAR129 (an IL-4R/OX40L bispecific antibody). These findings will be showcased via ePoster presentations. Picankibart, a cornerstone product in Innovent's pipeline, is anticipated to receive marketing approval by the end of the year, potentially offering a novel treatment option for psoriasis patients. The presentations aim to provide insight into the efficacy and safety of these innovative therapies and their potential impact on patient care.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN73327) on September 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2242644610.SGD","symbol_name":"Fidelity China Innovation A-ACC-SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250916:nNDL2jGYMn:1","article_id":"2567121313","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567121313","pubTimestamp":1757984424,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Innovent Biologics Inc., a prominent biopharmaceutical company, has announced that it will present multiple research results at the upcoming 34th European Academy of Dermatology and Venereology  Congress 2025 in Paris, France, from September 17-20. The presentations will include post hoc analysis of Phase 2 and Phase 3 clinical studies of IBI112 , as well as preclinical study results of IBI3013  and IAR129 . These findings will be showcased via ePoster presentations. Picankibart, a cornerstone product in Innovent's pipeline, is anticipated to receive marketing approval by the end of the year, potentially offering a novel treatment option for psoriasis patients. The presentations aim to provide insight into the efficacy and safety of these innovative therapies and their potential impact on patient care.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK1583":"高瓴概念","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK1589":"北水核心资产","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1161":"生物科技","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","01911":"华兴资本控股","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","BK1147":"投资银行业与经纪业","01801":"信达生物"},"translate_title":"信达生物在2025年EADV大会上宣布Picankibart治疗银屑病的有希望的临床研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01911":0.9,"01801":0.9},"content_text":"Innovent Biologics Announces Promising Clinical Study Results for Picankibart in Psoriasis at EADV Congress 2025\n    \n\nInnovent Biologics Inc., a prominent biopharmaceutical company, has announced that it will present multiple research results at the upcoming 34th European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, France, from September 17-20. The presentations will include post hoc analysis of Phase 2 and Phase 3 clinical studies of IBI112 (an IL-23p19 monoclonal antibody known as picankibart), as well as preclinical study results of IBI3013 (an IL-15 monoclonal antibody) and IAR129 (an IL-4R/OX40L bispecific antibody). These findings will be showcased via ePoster presentations. Picankibart, a cornerstone product in Innovent's pipeline, is anticipated to receive marketing approval by the end of the year, potentially offering a novel treatment option for psoriasis patients. The presentations aim to provide insight into the efficacy and safety of these innovative therapies and their potential impact on patient care.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN73327) on September 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}